The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 Beta, serum toll-like receptor-4 levels and Helicobacter pylori Cag A status

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 3, 2013, Pages 302-311

  Yakut, Mustafa ^a   Örmeci, Necati ^a   Erdal, Harun ^a   Keskin, Onur ^a   Karayel, Zihni ^a   Tutkak, Hüseyin ^a   Soykan, Irfan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CAGA PROTEIN; GASTRIN; INTERLEUKIN 1BETA; PEPSINOGEN; TOLL LIKE RECEPTOR 4; VASCULOTROPIN;

ADULT; ARTICLE; ATROPHIC GASTRITIS; AUTOIMMUNE ATROPHIC GASTRITIS; AUTOIMMUNE DISEASE; BACTERIUM DETECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPLASIA; FEMALE; GASTRIN BLOOD LEVEL; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; NONATROPHIC CHRONIC GASTRITIS; PEPSINOGEN BLOOD LEVEL; PRECANCER; PROTEIN BLOOD LEVEL; STOMACH LESION;

ADULT; AGED; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; FEMALE; GASTRINS; GASTRITIS; HELICOBACTER PYLORI; HUMANS; INTERLEUKIN-1BETA; MALE; METAPLASIA; MIDDLE AGED; PEPSINOGEN A; PEPSINOGEN C; PRECANCEROUS CONDITIONS; SENSITIVITY AND SPECIFICITY; STOMACH; STOMACH NEOPLASMS; TOLL-LIKE RECEPTOR 4; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878964532     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.09.013     Document Type: Article

References (30)

1. de Vries A.C., Meijer G.A., Looman C.W.N., Casparie M.K., Hansen B.E., van grieken N.C.T., et al. Epidemiological trends of pre-malignant gastric lesions:a long-term nationwide study in Netherlands. Gut 2007, 56:1665-1670.
2. Kang K.P., Lee H.S., Kim N., Kang H.M., Park Y.S., Lee D.H., et al. Role of intestinal metaplasia subtyping in the risk of gastric cancer in Korea. J Gastroenterol Hepatol 2009, 24(1):140-148.
3. de Vries A.C., Kuipers E.J. Epidemiology of premalignant gastric lesions:implications for the development of screening and surveillance strategies. Helicobacter 2007, 12(Suppl. 2):22-31.
4. Rugge M. Secondary prevention of gastric cancer. Gut 2007, 56:1646-1647.
5. Peek R.M. Prevention of gastric cancer: When is treatment of Helicobacter pylori warranted?. Therap Adv Gastroenterol 2008, 1:19-31.
6. Kang J.M., Kim N., Yoo J.Y., Park Y.S., Lee D.H., Kim H.Y., et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter 2008, 13:146-156.
7. Haj-Sheykholeslami A., Rakhshani N., Amirzargar A., Rafiee R., Shahidi S.M., Nikbin M., et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients:comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol 2008, 6:174-179.
8. Sipponen P., Ranta P., Helske T., Kääriäinen I., Mäki T., Linnala A., et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis:an observational case-control study. Scand J Gastroenterol 2002, 37:785-791.
9. Kikuchi R., Abe Y., Iijima K., Koike T., Ara N., Uno K., et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med 2011, 223:35-44.
10. Anagnostopoulos G.K., Stefanou D., Arkoumani E., Karagiannis J., Paraskeva K., Chalkley L., et al. Immunohistochemical expression of cell-cycle proteins in gastric precancerous lesions. J Gastroenterol Hepatol 2008, 23:626-631.
11. Lazǎr D., Tǎban S., Raica M., Sporea I., Cornianu M., Goldiş A., et al. Immunohistochemical evaluation of the tumor neoangiogenesis as a prognostic factor for gastric cancers. Rom J Morphol Embryol 2008, 49:137-148.
12. Raica M., Mogoantǎ L., Cîmpean A.M., Alexa A., Ioanovici S., Mǎrgǎritescu C., et al. Immunohistochemical expression of vascular endothelial growth factor (VEGF) in intestinal type gastric carcinoma. Rom J Morphol Embryol 2008, 49:37-42.
13. Achyut B.R., Ghoshal U.C., Moorchung N., Mittal B. Association of Toll-Like Receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Human Immunol 2007, 68:901-907.
14. Qian N., Chen X., Han S., Qiang F., Jin G., Zhou X., et al. Circulating IL-1beta levels, polymorphisms of IL-1B, and risk of cervical cancer in Chinese women. Cancer Res Clin Oncol 2010, 136:709-716.
15. Kamangar F., Cheng C., Abnet C.C., Rabkin C.S. Interleukin-1B polymorphisms and gastric cancer risk--a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15:1920-1928.
16. Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996, 20:1161-1181.
17. Rugge M., Correa P., Dixon M.F., Hattori T., Leandro G., Lewin K., et al. Gastric dysplasia:the Padova international classification. Am J Surg Pathol 2000, 24:167-176.
18. Con S.A., Con-Wong R., Con-Chin G.R., Con-Chin V.G., Takeuchi H., Valeren A.L., et al. Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica. Cancer Epidemiol Biomarkers Prev 2007, 16:2631-2636.
19. Sipponen P., Valle J., Varis K., Kekki M., Ihamäki T., Siurala M. Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa, an analysis of 860 subjects. Scand J Gastroenterol 1990, 25:513-519.
20. Oksanen A., Sipponen P., Karttunen R., Miettinen A., Veijola L., Sarna S., et al. Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy. Gut 2000, 46:460-463.
21. Vaananen H., Vaukonen M., Helske T., K;äriäinen I., Rasmussen M., Tunturi-Hihnala H., et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test, Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicenter study. Eur J Gastroenterol Hepatol 2003, 15:885-891.
22. Nardone G., Rocco A., Staibano S., Mezza E., Autiero G., Compare D., et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther 2005, 22:1139-1146.
23. Pasechnikov V.D., Chukov S.Z., Kotelevets S.M., Mostovov A.N., Mernova V.P., Polyakova M.B. Invasive and non-invasive diagnosis of Helicobacter pylori-associated atrophic gastritis:a comparative study. Scand J Gastroenterol 2005, 40:297-301.
24. Shiotani A., Iishi H., Uedo N., Kumamoto M., Nakae Y., Ishiguro S., et al. Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer 2005, 115:463-469.
25. Knight T., Wyatt J., Wilson A., Knight T., Newell D., Hengels K., et al. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high-risk groups. Br J Cancer 1996, 73:819-824.
26. Broutet N., Plebani M., Sakarovitch C., Sipponen P., Mégraud F. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer 2003, 88:1239-1247. Eurohepygast Study Group.
27. Karayiannakis A.J., Syrigos K.N., Polychronidis A., Zbar A., Kouraklis G., Simopoulos C., et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002, 236:37-42.
28. Annibale B., Negrini R., Caruana P., Lahner E., Grossi C., Bordi C., et al. Two-thirds of atrophic body gastritis patients have evidence of Helicobacter pylori infection. Helicobacter 2001, 6:225-233.
29. Lahner E., Di Giulio E., Caruana P., Ďmbra G., Milione M., Grossi C., et al. Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. Aliment Pharmacol Ther 2002, 16:507-514.
30. Feldman N., Cryer B., Lee E., Peterson W.L. Role of seroconversion in confirming cure of Helicobacter pylori infection. JAMA 1998, 280:363-365.